AI assistant
Verona Pharma plc — Director's Dealing 2024
Nov 2, 2024
30667_dirs_2024-11-01_d70492b3-f7ce-4ee4-9cc7-b91797c512f8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2024-10-30
Reporting Person: Fisher Andrew (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-10-30 | Ordinary Shares | A | 300000 | — | Acquired | 300000 | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 1/4th of the RSUs vesting on November 1, 2025 and the balance vesting in 12 equal quarterly installments thereafter.
F3: Consists of (i) 300,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 37,500 ADSs).